Literature DB >> 28980500

The advantages of switch to subcutaneous bortezomib in the real life.

Silvia Mangiacavalli1, Federica Cocito1, Virginia Valeria Ferretti1, Maya Ganzetti1, Claudio Salvatore Cartia1, Alessandro Corso1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28980500     DOI: 10.1080/10428194.2017.1382695

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  1 in total

1.  Clinical outcomes of bortezomib-based therapy in myeloma.

Authors:  Faouzi Djebbari; Anandagopal Srinivasan; Grant Vallance; Sally Moore; Jaimal Kothari; Karthik Ramasamy
Journal:  PLoS One       Date:  2018-12-12       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.